SCHEMBL3348331

SCHEMBL3348331

CC1=C(C#N)C(c2ccccc2)C(C#N)=C(C)N1c1nc(N2C(C)=C(C#N)C(c3ccccc3)C(C#N)=C2C)nc(N2C(C)=C(C#N)C(c3ccccc3)C(C#N)=C2C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CUL4A Q13619 1/20 0.47
ALDH1A1 P00352 12/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 10/20 0.40
HPGD P15428 5/20 0.40
KDM4E B2RXH2 7/20 0.40
GAA P10253 4/20 0.40
LMNA P02545 3/20 0.40
USP2 O75604 2/20 0.40
POLB P06746 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 2/20 0.38
PRNP P04156 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
BRCA1 P38398 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13295965 0.80 CUL4A (0.53) CUL4AALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3297515 0.76 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AMAPTHPGD
SCHEMBL11789191 0.75 CUL4A (0.49) CUL4AALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL7815153 0.70 KDM4E (0.60) CUL4AALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL7817485 0.66 ALDH1A1 (0.59) CUL4AALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL13295967 0.66 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15572548 0.65 CUL4A (1.00) CUL4AALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL17616704 0.62 ALDH1A1 (0.45) CUL4AALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL7814922 0.62 ALDH1A1 (0.54) CUL4AALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4442073 0.62 KMO (0.41) ALDH1A1MEN1KMT2AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732061-B2 A layer of a mixture of metal oxide and a 1,3,5-tris(N-heterocycl-N-yl)-s-triazine between the electrodes; prevention of an increase in thedriving voltage if film thickens; charge transfer compounds; luminescence; pixel displays with images of favorable reproducible color SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-06-08 US disclosed
US-20070194692-A1 Light emitting element and light emitting device having the light emittig element SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2007-08-23 US disclosed
WO-2006059734-A1 LIGHT EMITTING ELEMENT AND LIGHT EMITTING DEVICE HAVING THE LIGHT EMITTING ELEMENT SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2006-06-08 WO disclosed
US-7015324-B2 Triazine derivative and light emitting element and light emitting device including the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2006-03-21 US disclosed
US-20050225236-A1 Triazine derivative and light emitting element and light emitting device including the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050225236-A1 Triazine derivative and light emitting element and light emitting device including the same NR2E3, IL5, NOX5 CUL4A 2255/4885ALDH1A1 595/4885SMN1; SMN2 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.